{
    "clinical_study": {
        "@rank": "151353", 
        "arm_group": {
            "arm_group_label": "Treatment (clofarabine, melphalan, transplant)", 
            "arm_group_type": "Experimental", 
            "description": "CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 20 minutes on day -4.\nTRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.\nGVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper beginning on day 100 or 180."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well clofarabine and melphalan before a donor stem cell\n      transplant works in treating patients with myelodysplasia or acute leukemia in remission.\n      Giving chemotherapy, such as clofarabine and melphalan, before a donor stem cell transplant\n      helps stop the growth of cancer cells. It may also stop the patient's immune system from\n      rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into\n      a patient they may help the patient's bone marrow make stem cells, red blood cells, white\n      blood cells, and platelets."
        }, 
        "brief_title": "Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission", 
        "condition": [
            "Adult Acute Lymphoblastic Leukemia in Remission", 
            "Adult Acute Myeloid Leukemia in Remission", 
            "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", 
            "Adult Acute Myeloid Leukemia With Del(5q)", 
            "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", 
            "de Novo Myelodysplastic Syndromes", 
            "Previously Treated Myelodysplastic Syndromes", 
            "Secondary Acute Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Acute Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Following a patient safety lead-in, determine the anti-tumor activity of clofarabine\n      given in combination with high-dose melphalan as assessed by 2-year progression-free\n      survival (PFS).\n\n      II. Estimate overall survival (OS), cumulative incidence (CI) of relapse/progression and\n      non-relapse mortality (NRM) at 100 days, 1 year and 2 years.\n\n      III. Summarize toxicities/complications by organ and severity, including acute and chronic\n      graft-vs-host disease (GVHD), and infection.\n\n      OUTLINE:\n\n      CONDITIONING REGIMEN: Patients receive clofarabine intravenously (IV) over 2 hours on days\n      -9 to -5 and melphalan IV over 20 minutes on day -4.\n\n      TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.\n\n      GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or orally (PO) and\n      sirolimus PO once daily with taper beginning on day 100 or 180.\n\n      After completion of study treatment, patients are followed up on 30, 100, and 180 days, and\n      then yearly for 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients in 1st or 2nd remission with acute myeloid leukemia (AML) or acute\n             lymphoblastic leukemia (ALL) (no circulating blasts, < 5% myeloblasts in the bone\n             marrow, normalization of previously detected cytogenetic abnormalities, no\n             extramedullary disease )\n\n          -  High risk myelodysplastic syndrome (MDS) (not myeloproliferative neoplasms)\n\n               -  Intermediate II and high risk by International Prognostic Scoring System (IPSS)\n\n               -  Intermediate, high, or very high by World Health Organization (WHO)\n                  classification-based Prognostic Scoring System (WPSS)\n\n               -  Transfusion dependent\n\n               -  Patients with MDS that has evolved to AML must be in remission\n\n          -  Patient must not be eligible for full ablative regimens by the attending physician\n\n          -  Performance status of >= 70% on the Karnofsky scale\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control or abstinence) prior to study entry and\n             for six months following duration of study participation; should a woman become\n             pregnant or suspect she is pregnant while participating on the trial, she should\n             inform her treating physician immediately\n\n          -  Bone marrow and peripheral blood studies must be available for confirmation of\n             diagnosis; cytogenetics, flow cytometry, and molecular studies (such as fms-related\n             tyrosine kinase 3 [Flt-3] status) will be obtained as per standard practice\n\n          -  Bone marrow aspirates/biopsies should be performed within 14 days from the start of\n             the conditioning regimen to confirm disease remission status\n\n          -  A pretreatment measured creatinine clearance (absolute value) of >= 60 mL/minute\n\n          -  Patients must have a serum bilirubin =< 2.0 mg/dl\n\n          -  Patients must have serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate\n             pyruvate transaminase (SGPT) =< 2.5 times the institutional upper limit of normal\n\n          -  Ejection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) >\n             50%\n\n          -  Diffusing capacity of the lung for carbon monoxide (DLCO) or forced expiratory volume\n             in 1 second (FEV1) > 45% predicted\n\n          -  Availability of an human leukocyte antigen (HLA) matched (6/6) sibling donor or 8/8\n             matched unrelated donor (no mismatch allowed in HLA-A, HLA-B, HLA-C and HLA-DR,\n             donors with mismatch HLA-DQ or HLA-DPH are eligible)\n\n          -  Donor stem cell source can be either peripheral blood or bone marrow\n\n          -  All patients must have a psychosocial evaluation prior to transplant as per City of\n             Hope (COH) standard operating procedure (SOP)\n\n          -  All subjects must have the ability to understand and the willingness to sign a\n             written informed consent\n\n          -  Patients who received chemotherapy (induction or consolidation) can proceed to\n             transplant once their counts have recovered (absolute neutrophil count [ANC] > 1000,\n             platelets > 100,000)\n\n        Exclusion Criteria:\n\n          -  Patients who have received a prior autologous or allogeneic transplant are excluded\n\n          -  Patients with significant hepatic dysfunction (not meeting liver function tests [LFT]\n             eligibility criteria)\n\n          -  Patients with myelofibrosis or AML evolved from myelofibrosis\n\n          -  Patients with MDS evolved into AML that is not in remission\n\n          -  Patients with acute promyelocytic leukemia - Patients with myeloproliferative\n             neoplasms\n\n          -  Patients with suspected or proven central nervous system (CNS) leukemia (diagnostic\n             lumbar puncture not required before enrollment)\n\n          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active or\n             poorly controlled infection, symptomatic congestive heart failure, unstable angina\n             pectoris, cardiac arrhythmia, poorly controlled pulmonary disease or psychiatric\n             illness/social situations that would limit compliance with study requirements\n\n          -  Pregnant or lactating women are excluded from this study\n\n          -  Patients who do not agree to practice effective forms of contraception\n\n          -  Human immunodeficiency virus (HIV)-positive patients are excluded from this study\n\n          -  Patients are excluded if they are Hepatitis B sAg, Hep B cAg, Hep B cAb, or Hep C\n             positive\n\n          -  Patients who have received radiation therapy as part of their leukemia treatment may\n             be ineligible and individual cases must be presented to the study principal\n             investigator (PI) for determination of eligibility\n\n          -  Any psychiatric, social or compliance issues that, in the treating physician's\n             opinion, will interfere with completion of the transplant treatment and follow up\n\n          -  Medical or psychiatric reasons which make the donor unlikely to tolerate or cooperate\n             with filgrastim (G-CSF) therapy or leukapheresis or bone marrow harvest\n\n          -  Known allergies to clofarabine, melphalan, sirolimus or tacrolimus\n\n          -  Patients with other active malignancies (besides AML, ALL, MDS) requiring treatment\n             or where there is concern of progression are ineligible for this study; however,\n             patients with previously treated skin cancer, early stage cervical or prostate cancer\n             may be eligible if there is no evidence of residual disease\n\n          -  Cord blood as a donor source is not acceptable\n\n          -  Subjects, who in the opinion of the investigator, may not be able to comply with the\n             safety monitoring requirements of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "77", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885689", 
            "org_study_id": "13130", 
            "secondary_id": [
                "NCI-2013-01193", 
                "P30CA033572"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (clofarabine, melphalan, transplant)", 
                "description": "Given IV", 
                "intervention_name": "clofarabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CAFdA", 
                    "Clofarex", 
                    "Clolar"
                ]
            }, 
            {
                "arm_group_label": "Treatment (clofarabine, melphalan, transplant)", 
                "description": "Given IV", 
                "intervention_name": "melphalan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Alkeran", 
                    "CB-3025", 
                    "L-PAM", 
                    "L-phenylalanine mustard", 
                    "L-Sarcolysin"
                ]
            }, 
            {
                "arm_group_label": "Treatment (clofarabine, melphalan, transplant)", 
                "description": "Undergo allogeneic hematopoietic stem cell transplant", 
                "intervention_name": "allogeneic hematopoietic stem cell transplantation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Treatment (clofarabine, melphalan, transplant)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment (clofarabine, melphalan, transplant)", 
                "description": "Given IV or PO", 
                "intervention_name": "tacrolimus", 
                "intervention_type": "Drug", 
                "other_name": [
                    "FK 506", 
                    "Prograf"
                ]
            }, 
            {
                "arm_group_label": "Treatment (clofarabine, melphalan, transplant)", 
                "description": "Given PO", 
                "intervention_name": "sirolimus", 
                "intervention_type": "Drug", 
                "other_name": [
                    "AY 22989", 
                    "Rapamune", 
                    "rapamycin", 
                    "SLM"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Melphalan", 
                "Clofarabine", 
                "Sirolimus", 
                "Everolimus", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 31, 2014", 
        "location": {
            "contact": {
                "email": "skhaled@coh.org", 
                "last_name": "Samer K. Khaled, MD", 
                "phone": "800-826-4673"
            }, 
            "facility": {
                "address": {
                    "city": "Duarte", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91010"
                }, 
                "name": "City of Hope Medical Center"
            }, 
            "investigator": {
                "last_name": "Samer K. Khaled", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Myelodysplasia or Acute Leukemia in Remission", 
        "overall_official": {
            "affiliation": "City of Hope Medical Center", 
            "last_name": "Samer Khaled", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2021", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Calculated using the Kaplan-Meier product-limit method.", 
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "From start of treatment to the date of death, disease relapse/progression, or last follow-up whichever occurs first, assessed at 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885689"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Calculated using the Kaplan-Meier product-limit method.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From start of treatment until death, or last follow-up, whichever comes first, assessed up to 5 years"
            }, 
            {
                "description": "Calculated as competing risks using the Gray method.", 
                "measure": "Cumulative incidence of relapse/progression", 
                "safety_issue": "No", 
                "time_frame": "From start of treatment, assessed up to 5 years"
            }, 
            {
                "description": "Calculated as competing risks using the Gray method.", 
                "measure": "Cumulative incidence of non-relapse mortality defined as death occurring in a patient from causes other than relapse or progression", 
                "safety_issue": "No", 
                "time_frame": "From start of treatment until non-disease death, assessed up to 5 years"
            }, 
            {
                "description": "Toxicity information recorded will include the type, severity, and the probable association with the study regimen. Tables will be constructed to summarize the observed incidence by severity and type of toxicity.", 
                "measure": "Overall toxicity graded using the Bearman scale and CTCAE v4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 100 days post-transplant"
            }, 
            {
                "description": "The first day of acute GVHD onset at a certain grade will be used to calculate cumulative incidence curves for that GVHD grade.", 
                "measure": "Incidence and severity of acute GVHD of grades 2-4 and 3-4 according to the consensus grading", 
                "safety_issue": "No", 
                "time_frame": "Up to 100 days post-transplant"
            }, 
            {
                "description": "The first day of chronic GVHD onset will be used to calculate cumulative incidence curves.", 
                "measure": "Incidence and severity of chronic GVHD scored according to National Institute of Health (NIH) consensus staging", 
                "safety_issue": "No", 
                "time_frame": "After 100 days post-transplant"
            }, 
            {
                "measure": "Microbiologically documented infection", 
                "safety_issue": "No", 
                "time_frame": "Up to 100 days post-transplant"
            }
        ], 
        "source": "City of Hope Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "City of Hope Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}